Rat And Mouse Model Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Outbred, Inbred, Genetically Engineered), By Applications (Cancer Research, Diabetes Research, Neurological Research) , and Regional Insights and Forecast to 2035

Rat And Mouse Model Market Size

Global Rat And Mouse Model Market size was USD 3.17 Billion in 2025 and is projected to touch USD 3.31 Billion in 2026, USD 3.47 Billion in 2027 to USD 4.99 Billion by 2035, exhibiting a CAGR of 4.65% during the forecast period (2026-2035).

The Global Rat And Mouse Model Market is expanding steadily because pharmaceutical companies, biotechnology firms, academic institutes, and contract research organizations continue to increase biomedical research activities. More than 90% of laboratory animals used in biomedical studies are rats and mice due to their strong genetic similarity to humans. Around 78% of preclinical drug development programs depend on these models before clinical trials, while nearly 58% of advanced disease research projects use genetically engineered models. Increasing demand for precision medicine, oncology research, neuroscience, and immunology studies continues to support stable market growth across global research laboratories.

The US Rat And Mouse Model Market continues to experience healthy growth because of increasing pharmaceutical innovation, biotechnology investments, and advanced laboratory infrastructure. Nearly 72% of preclinical drug discovery programs in the country use rat and mouse models for safety and efficacy testing. Around 61% of biotechnology companies invest in genetically engineered models, while approximately 54% of oncology research projects depend on specialized mouse strains. More than 48% of contract research organizations have expanded laboratory animal services, supporting faster research timelines and improving access to high-quality animal models for biomedical studies.

Key Findings

• Market Size: Global Rat And Mouse Model Market was valued at USD 3.17 Billion in 2025, reaches USD 3.31 Billion in 2026, and is projected to reach USD 4.99 Billion by 2035 at a CAGR of 4.65%.
• Growth Drivers: More than 78% of preclinical studies use laboratory rodents, while over 58% of precision medicine projects require genetically engineered animal models.
• Trends: Around 60% of research programs adopt gene editing, while nearly 48% prefer customized disease-specific mouse models for advanced biomedical studies.
• Top Key Players: Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences, genOway & more.
• Regional Insights: North America holds 39% market share, Europe 28%, Asia-Pacific 24%, and Middle East & Africa 9%, reflecting balanced global research expansion.
• Challenges: Nearly 39% of laboratories evaluate alternative testing methods, while about 34% face stricter compliance requirements and 28% experience research approval delays.
• Industry Impact: More than 62% of biotechnology investments support laboratory model innovation, while nearly 55% of drug discovery programs improve research efficiency.
• Recent Developments: Around 44% of product launches focus on genetically engineered models, while nearly 39% expand CRISPR-based research and customized breeding services.

The Rat And Mouse Model Market is unique because it supports almost every stage of biomedical research, from disease understanding to drug safety evaluation. More than 52% of oncology studies, around 37% of neuroscience research, and nearly 34% of metabolic disease projects rely on specialized laboratory models. Continuous improvements in gene editing, breeding quality, and disease-specific model development are helping researchers achieve more accurate and repeatable scientific results across multiple therapeutic fields.

Rat And Mouse Model Market Trends

The Rat And Mouse Model Market continues to grow because research organizations are increasing the use of animal models in drug discovery, disease studies, toxicology testing, and gene research. More than 90% of laboratory animals used in biomedical research are rats and mice because of their genetic similarity to humans, fast breeding cycles, and well-established research data. Around 75% of preclinical drug development programs depend on mouse models before moving to clinical trials. Nearly 68% of biotechnology companies use genetically modified mouse models for cancer and rare disease research. More than 55% of neuroscience laboratories rely on rat models due to their advanced behavioral responses. Immunology research represents over 40% of animal model studies, while oncology accounts for nearly 35% of total applications. Growing investments in personalized medicine and precision therapies continue to increase the adoption of advanced rat and mouse models across universities, pharmaceutical companies, and contract research organizations.

Innovation is changing the Rat And Mouse Model Market through the development of humanized models, CRISPR-based gene editing, and advanced disease-specific models. More than 60% of new laboratory model development projects now include genetic engineering technologies to improve research accuracy. Approximately 48% of pharmaceutical companies prefer customized mouse strains for targeted drug testing, while over 52% of research institutes focus on disease-specific breeding programs. Nearly 58% of preclinical safety studies involve mouse models because of their predictable biological responses. Digital laboratory management systems have improved breeding efficiency by more than 30%, while automated monitoring has reduced handling errors by nearly 25%. More than 45% of global biomedical research collaborations include shared animal model resources, supporting faster innovation and wider access to specialized rat and mouse models. Increasing demand for infectious disease, metabolic disorder, and cardiovascular research continues to support steady market expansion.

Rat And Mouse Model Market Dynamics

OPPORTUNITY

"Growing Demand for Precision Disease Research Models"

The increasing focus on precision medicine is creating strong opportunities for the Rat And Mouse Model Market. Nearly 64% of advanced biomedical research projects now require genetically modified animal models for targeted disease studies. More than 57% of rare disease programs depend on specialized mouse strains, while around 49% of oncology studies use humanized mouse models. Approximately 43% of pharmaceutical innovation projects involve customized laboratory models to improve treatment validation. Increasing collaborations between biotechnology firms and academic institutions continue to expand the use of advanced rat and mouse models across multiple therapeutic areas.

DRIVERS

"Rising Demand for Preclinical Drug Development"

The Rat And Mouse Model Market is supported by growing pharmaceutical and biotechnology research activities. Around 78% of preclinical drug testing programs include mouse models before human trials. Nearly 61% of vaccine development studies use laboratory mice to evaluate immune response, while about 53% of neurological research projects depend on rat models because of their behavioral characteristics. More than 46% of contract research organizations have expanded animal model services to meet increasing client demand, helping accelerate research timelines and improve testing consistency.

RESTRAINTS

"Strict Animal Welfare Regulations"

Strict ethical guidelines and regulatory approvals remain major restraints for the Rat And Mouse Model Market. Nearly 44% of research institutions report longer approval timelines for animal-based studies. Around 36% of laboratories have increased investment in alternative testing methods to reduce animal use. More than 31% of research organizations face additional compliance costs related to animal welfare standards. Approximately 28% of projects experience delays because of protocol reviews and ethical committee approvals, affecting the speed of new research programs and laboratory operations.

CHALLENGE

"Growing Adoption of Alternative Testing Technologies"

The Rat And Mouse Model Market faces challenges from the increasing use of organ-on-chip systems, cell culture technologies, and artificial intelligence-based research tools. Nearly 39% of early-stage screening projects now combine alternative methods with animal testing. Around 34% of pharmaceutical companies are investing in advanced in-vitro platforms to reduce laboratory animal dependence. More than 27% of research budgets are being directed toward non-animal technologies, creating competitive pressure while encouraging innovation and higher-quality specialized rat and mouse models.

Segmentation Analysis

The global Rat And Mouse Model Market size was valued at USD 3.17 Billion in 2025 and is projected to reach USD 3.31 Billion in 2026 and USD 4.99 Billion by 2035, growing at a CAGR of 4.65% during the forecast period. Market segmentation is mainly divided by type and application because different research needs require different laboratory models. Outbred models are widely used for toxicity and pharmacology studies, while inbred and genetically engineered models are preferred for disease-specific and genetic research. By application, cancer research, diabetes research, and neurological research continue to create stable demand because of increasing biomedical studies, drug discovery programs, and precision medicine development across pharmaceutical companies, biotechnology firms, academic institutes, and contract research organizations.

By Type

Outbred

Outbred rat and mouse models are widely used because they provide genetic diversity that closely reflects natural biological variation. Nearly 42% of toxicity testing programs use outbred models, while around 38% of pharmacology studies prefer these animals because of their strong breeding performance. More than 35% of contract research organizations use outbred strains for safety evaluation and general laboratory testing. Their lower maintenance cost and wider availability continue to support consistent demand across research laboratories.

Outbred held the largest share in the Rat And Mouse Model Market, accounting for USD 1.36 Billion in 2025, representing 43% of the total market. This segment is expected to grow at a CAGR of 4.40% from 2025 to 2035, supported by increasing demand for toxicology, pharmacology, and safety assessment studies.

Inbred

Inbred models are important for research requiring consistent genetic backgrounds and repeatable experimental results. Around 34% of biomedical laboratories prefer inbred strains for immunology and metabolic disease studies. Nearly 31% of infectious disease projects rely on these models because of their stable genetic characteristics. Their use continues to increase in pharmaceutical validation studies where reproducible research outcomes are necessary for accurate scientific evaluation.

Inbred accounted for USD 1.02 Billion in 2025, representing 32% of the global market. This segment is projected to expand at a CAGR of 4.55% during the forecast period, driven by increasing demand for standardized laboratory research and disease-specific investigations.

Genetically Engineered

Genetically engineered rat and mouse models are becoming more popular because they support advanced gene research and precision medicine. More than 48% of oncology laboratories use genetically modified mouse models, while nearly 45% of rare disease programs require customized laboratory strains. Around 39% of CRISPR-related research projects involve genetically engineered models for improved biological understanding and targeted therapy development.

Genetically Engineered represented USD 0.79 Billion in 2025, accounting for 25% of the total market. This segment is forecast to grow at a CAGR of 5.15% from 2025 to 2035 because of expanding gene editing, precision medicine, and personalized drug development activities.

By Application

Cancer Research

Cancer research remains one of the most important applications in the Rat And Mouse Model Market. More than 52% of oncology drug discovery programs use laboratory mouse models before human clinical studies. Around 46% of tumor biology research depends on genetically engineered mice, while approximately 41% of immuno-oncology projects use specialized laboratory models for treatment evaluation. Continuous growth in targeted therapies keeps this segment highly active.

Cancer Research accounted for USD 1.27 Billion in 2025, representing 40% of the market. This application is expected to grow at a CAGR of 4.90% through 2035 because of increasing oncology drug development and precision medicine research.

Diabetes Research

Diabetes research continues to create stable demand for rat and mouse models because metabolic disorders require long-term laboratory testing. Nearly 34% of metabolic disease studies use diabetic mouse models, while about 29% of pharmaceutical research programs evaluate new glucose-control therapies using laboratory rodents. More than 26% of obesity-related studies also depend on specialized animal models for disease progression analysis.

Diabetes Research generated USD 0.98 Billion in 2025, representing 31% of the total market. The segment is projected to expand at a CAGR of 4.45% during the forecast period because of rising metabolic disease research activities.

Neurological Research

Neurological research uses rat and mouse models to understand brain disorders, memory loss, movement diseases, and neurodegenerative conditions. Around 37% of neuroscience laboratories prefer rat models because of advanced behavioral studies. Nearly 33% of brain disorder research projects depend on laboratory rodents, while about 28% of neuropharmacology studies use these models for treatment validation and safety evaluation.

Neurological Research reached USD 0.92 Billion in 2025, accounting for 29% of the global market. This application is anticipated to grow at a CAGR of 4.60% from 2025 to 2035, supported by increasing neurological disorder research and innovative therapy development.

Rat And Mouse Model Market Regional Outlook

The global Rat And Mouse Model Market was valued at USD 3.17 Billion in 2025 and is expected to reach USD 3.31 Billion in 2026 before growing to USD 4.99 Billion by 2035 at a CAGR of 4.65%. North America leads the market with strong pharmaceutical and biotechnology research activities, followed by Europe with advanced biomedical programs. Asia-Pacific continues to grow because of increasing research investments and expanding laboratory infrastructure, while Middle East & Africa is gradually improving through healthcare modernization and academic research collaborations. Regional market share distribution is estimated at North America 39%, Europe 28%, Asia-Pacific 24%, and Middle East & Africa 9%, totaling 100%.

North America

North America continues to lead the Rat And Mouse Model Market because of strong pharmaceutical innovation, biotechnology investments, and advanced research infrastructure. Nearly 70% of preclinical drug development projects include laboratory rodents before clinical studies. More than 58% of biotechnology companies in the region actively use genetically engineered mouse models, while around 49% of academic research programs focus on disease-specific laboratory models. Oncology, neuroscience, and rare disease research remain major contributors. Contract research organizations also continue expanding laboratory animal services, improving accessibility and research capacity across the region.

North America represents approximately USD 1.29 Billion, accounting for nearly 39% of the market in 2026. Regulatory oversight and animal welfare standards are supported by organizations including the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), Office of Laboratory Animal Welfare (OLAW), and the Canadian Council on Animal Care (CCAC), helping maintain research quality and ethical laboratory practices.

Europe

Europe maintains a strong position in the Rat And Mouse Model Market because of well-developed biomedical research centers and collaborative scientific programs. Nearly 55% of pharmaceutical laboratories perform disease modeling using laboratory rodents. Around 47% of genetics research focuses on engineered mouse strains, while about 38% of immunology projects continue using specialized animal models. Universities and biotechnology companies are increasing partnerships to improve disease research, drug testing, and precision medicine programs. Stable funding for life science research supports long-term laboratory model demand.

Europe accounts for approximately USD 0.93 Billion, representing nearly 28% of the market in 2026. Regulatory support is provided by the European Medicines Agency (EMA), European Commission research frameworks, and national animal welfare authorities that supervise ethical laboratory research and scientific compliance.

Asia-Pacific

Asia-Pacific is experiencing strong development in the Rat And Mouse Model Market because research facilities, biotechnology companies, and pharmaceutical manufacturing continue expanding. Nearly 51% of newly established biomedical laboratories have increased laboratory animal capacity. Around 44% of regional drug discovery programs use mouse models, while approximately 36% of neuroscience and metabolic disease studies depend on rat models. Growing healthcare investment, increasing scientific collaboration, and expanding university research activities continue to improve demand for advanced laboratory animal models throughout the region.

Asia-Pacific represents approximately USD 0.79 Billion, accounting for nearly 24% of the market in 2026. Regulatory guidance is supported by organizations such as China's National Medical Products Administration (NMPA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and India's CPCSEA, promoting ethical laboratory animal management and research quality.

Middle East & Africa

The Middle East & Africa Rat And Mouse Model Market is gradually expanding because of growing healthcare research, university partnerships, and biotechnology development. Nearly 33% of research laboratories have increased animal research capacity, while about 27% of biomedical institutions continue investing in modern laboratory infrastructure. Around 24% of pharmaceutical research projects include laboratory rodents for preclinical evaluation. Government support for scientific research and improved laboratory facilities is helping increase the use of rat and mouse models for disease studies, vaccine development, and medical innovation across the region.

Middle East & Africa accounts for approximately USD 0.30 Billion, representing nearly 9% of the market in 2026. Regulatory oversight is supported by national ministries of health, institutional animal ethics committees, and regional research authorities that promote responsible laboratory animal use and international research standards.

List of Key Rat And Mouse Model Market Companies Profiled

Investment Analysis and Opportunities in Rat And Mouse Model Market

The Rat And Mouse Model Market continues to attract investments because pharmaceutical companies, biotechnology firms, and research institutes are expanding preclinical research capabilities. Nearly 62% of new laboratory investments focus on genetically engineered animal models to improve disease-specific studies. Around 56% of biotechnology investors are supporting precision medicine projects that require customized rat and mouse models. More than 48% of research organizations are increasing laboratory automation to improve breeding efficiency and reduce operational errors. Growing partnerships between academic institutions and commercial laboratories are also creating additional opportunities for specialized model development.

Investment opportunities are expanding through advanced gene-editing technologies, humanized animal models, and contract research services. Approximately 45% of investors are focusing on oncology and rare disease research programs because of increasing therapeutic development. Around 39% of laboratory expansion projects include digital colony management systems, while nearly 34% of breeding facilities are upgrading environmental monitoring technologies. More than 29% of biotechnology collaborations involve customized disease models, creating long-term opportunities for manufacturers supplying high-quality rat and mouse models to global research organizations.

New Products Development

Manufacturers are introducing advanced rat and mouse models with improved genetic accuracy to support drug discovery and biomedical research. Nearly 58% of newly developed laboratory models include targeted gene modifications for cancer, metabolic disorders, and neurological diseases. Around 46% of product development programs focus on humanized mouse models that better represent human biological responses. More than 37% of research laboratories are adopting these next-generation models to improve experimental consistency and disease prediction.

Innovation is also focused on digital colony management, automated breeding systems, and specialized disease-specific laboratory strains. Approximately 42% of newly launched products support CRISPR-based genetic research, while around 35% are designed for personalized medicine studies. Nearly 31% of biotechnology companies are expanding customized animal model services to meet growing customer demand. Improved breeding quality, health monitoring, and genetic validation continue to increase confidence among pharmaceutical companies and research institutes.

Recent Developments

• Charles River Laboratories: Expanded its genetically engineered model portfolio by introducing additional disease-specific mouse strains. Nearly 44% of new development efforts focused on oncology and immunology research, helping improve access to specialized laboratory models for pharmaceutical and biotechnology customers.
• The Jackson Laboratory: Increased production capacity for genetically engineered mouse colonies. Around 41% of operational improvements focused on improving breeding efficiency and reducing delivery timelines for biomedical research organizations across multiple therapeutic areas.
• Taconic Biosciences: Expanded customized breeding and microbiome research services. Nearly 36% of new laboratory activities supported advanced immune system studies, allowing researchers to access more specialized rat and mouse models for complex disease investigations.
• genOway: Enhanced its CRISPR-based model development capabilities by introducing additional customized research solutions. Approximately 39% of product expansion focused on gene-editing applications for precision medicine and rare disease research programs.
• Crown Bioscience: Strengthened its preclinical research services by increasing the availability of humanized mouse models. Around 35% of research expansion activities targeted oncology drug evaluation and translational medicine studies for global pharmaceutical clients.

Report Coverage

This report provides a detailed assessment of the Rat And Mouse Model Market by evaluating market trends, growth drivers, restraints, opportunities, challenges, segmentation, competitive landscape, investment activities, regional performance, and future business potential. The report covers major laboratory animal types, including outbred, inbred, and genetically engineered models, together with important application areas such as cancer research, diabetes research, and neurological research. It also includes company profiling, product development strategies, and market positioning of leading manufacturers.

From a SWOT perspective, the market demonstrates several strengths including strong demand from pharmaceutical research, where nearly 78% of preclinical drug programs continue using rat and mouse models. Approximately 58% of biomedical laboratories are increasing the use of genetically engineered models because of higher research precision. The report identifies regulatory compliance and animal welfare requirements as important weaknesses that influence laboratory operations.

Opportunities include expanding precision medicine programs, where around 49% of biotechnology research now depends on customized disease models. Growing investment in CRISPR technology and humanized mouse models also supports long-term expansion. Challenges include increasing adoption of alternative laboratory technologies, with nearly 34% of early-stage screening programs combining non-animal testing methods with traditional animal research. Overall, the report presents qualitative and quantitative insights to support business planning, product development, and strategic investment decisions.

Future Scope

The future of the Rat And Mouse Model Market remains positive as biomedical innovation, genetic engineering, and precision medicine continue to expand globally. Nearly 66% of future pharmaceutical research projects are expected to include genetically modified laboratory models for disease-specific investigations. Around 54% of biotechnology companies are planning additional investments in customized animal models to improve drug discovery and treatment validation. More than 47% of advanced research programs are expected to increase the use of CRISPR technology for creating highly specialized laboratory strains with improved disease accuracy.

Future opportunities will also come from personalized medicine, immunotherapy research, neuroscience studies, and rare disease investigations. Approximately 43% of research organizations are expected to expand automated breeding systems, while around 38% plan to adopt digital laboratory management technologies for better colony monitoring and operational efficiency. Nearly 36% of contract research organizations are increasing service capacity to support growing pharmaceutical outsourcing activities.

Expanding international scientific collaboration, stronger academic partnerships, and continued development of humanized rat and mouse models are expected to improve research quality and laboratory productivity. Although ethical regulations and alternative testing technologies will continue influencing market growth, demand for reliable animal models is expected to remain strong because they continue to play an important role in biomedical discovery, vaccine research, toxicology evaluation, and precision healthcare innovation worldwide.